DadFinStart your free week
DadFin › Stocks › Healthcare › BDX

Becton, Dickinson and Company (BDX) stock score

Healthcare · Medical Instruments & Supplies · United States

$183.75 ▲ +0.55% today

69.8
Dad Score, out of 100
middling

Becton, Dickinson and Company (BDX) is a Medical Instruments & Supplies company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 69.8 out of 100 on the Dad Score, a middling reading that places the business ahead of 70% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #258 of 974. Its strongest axes are valuation, quality and growth; its weakest are price action and conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Strong
Growth
Above average
Price action
Below average
Risk
Strong
Conviction
Below average
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)30.6×
P/E (forward)13.3×
Dividend yield2.35%
Return on capital5.3%
Operating margin15.7%
Revenue growth (YoY)+8.2%
FCF yield4.0%
Net debt / EBITDA2.63×
Piotroski F-Score7 / 9
52-week change+20.1%
Market cap$48.2B
Next earningsNov 5, 2026

What subscribers see on BDX

Start your free weekSubscriber? Open the full research →

Medical Instruments & Supplies peers

StockCompanyDad ScoreBandMarket cap
ISRGIntuitive Surgical, Inc.87.0strong$140.4B
MDLNMedline Inc.98.2strong$47.9B
ALCAlcon Inc.64.6middling$30.8B
RMDResMed Inc.94.3strong$30.8B
WSTWest Pharmaceutical Services, Inc.90.1strong$25.7B
SOLVSolventum Corporation71.9good$15.0B
BAXBaxter International Inc.40.5middling$12.1B
COOThe Cooper Companies, Inc.99.6strong$10.8B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.